Page last updated: 2024-11-13

chebulic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chebulic acid: from the ripe fruits of Terminalia chebula [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
TerminaliagenusA plant genus of the family COMBRETACEAE. Members contain arjunin, an ellagitannin (TANNINS).[MeSH]CombretaceaeA plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mostly trees and shrubs growing in warm areas.[MeSH]
Terminalia chebulaspecies[no description available]CombretaceaeA plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mostly trees and shrubs growing in warm areas.[MeSH]

Cross-References

ID SourceID
PubMed CID71308174
CHEMBL ID4129076
MeSH IDM0574303

Synonyms (17)

Synonym
chebulic acid
23725-05-5
(2s)-2-[(3s,4s)-3-carboxy-5,6,7-trihydroxy-1-oxo-isochroman-4-yl]butanedioic acid
HY-N4170
Q5089008
CS-0032300
(2s)-2-[(3s,4s)-3-carboxy-5,6,7-trihydroxy-1-oxo-3,4-dihydroisochromen-4-yl]butanedioic acid
(s)-2-((3s,4s)-3-carboxy-5,6,7-trihydroxy-1-oxoisochroman-4-yl)succinic acid
(2s)-[(3s,4s)-3-carboxy-3,4-dihydro-5,6,7-trihydroxy-1-oxo-1h-2-benzopyran-4-yl]butanedioic acid
MS-25570
CHEMBL4129076
(2s)-2-[(3s)-3,4-dihydro-3alpha-carboxy-5,6,7-trihydroxy-1-oxo-1h-2-benzopyran-4beta-yl]butanedioic acid
YAA72505
4-isochromansuccinic acid, 3-carboxy-5,6,7-trihydroxy-1-oxo-
butanedioic acid, (3-carboxy-3,4-dihydro-5,6,7-trihydroxy-1-oxo-1h-2-benzopyran-4-yl)-, (3s-(3.alpha.,4.beta.(r*)))-
butanedioic acid, ((3s,4s)-3-carboxy-3,4-dihydro-5,6,7-trihydroxy-1-oxo-1h-2-benzopyran-4-yl)-, (2s)-
AKOS040760120

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" chebula ethanol extracts gave no adverse effects at dosages of 2000 mg/kg in rats in the study."( Mutagenicity and oral toxicity studies of Terminalia chebula.
Hong, CO; Jun, W; Kim, JH; Koo, YC; Lee, KW; Yang, SY, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1494599Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Anticomplement compounds from Polygonum chinense.
AID1494600Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Anticomplement compounds from Polygonum chinense.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (72.73)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.32 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]